Reducing the NCD morbidity and mortality

Slides:



Advertisements
Similar presentations
1 What do we know about access to chronic disease medicines ? Dr Shanthi Mendis Coordinator Chronic Diseases Prevention and Management Department of Chronic.
Advertisements

CVD risk estimation and prevention: An overview of SIGN 97.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
1 Integration of Noncommunicable Diseases into PHC in low-resource settings Lessons learned Dr Shanthi Mendis Chronic Disease Prevention and Management.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
JBS2 Some highlights from the JBS2 guidelines on prevention of cardiovascular disease in clinical practice Jim McMorran GP trainer Visiting Senior Clinical.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Clinical Issues in the Management of Non Communicable Diseases Dr Gyaneshwar Rao Colonial War Memorial Hospital Suva.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
WHO Technical Briefing Seminar on Essential Medicines & Health Products, October 2013 Noncommunicable Diseases –Action Plan Dr Shanthi Mendis Director,
ASSIGN Paul Ryan, Clinical Director, North Glasgow CHCP.
Salt, Heart Disease, and Stroke Norm Campbell. 1) The role of increased blood pressure as a determinant of adverse outcomes 2) The health risks of high.
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
Polypill x Aspirin Project Groups 3 and 4
Dr. Rohit A, Dr Balu P S Public Health Specialist [ NCD] India
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
The Burden of Chronic Diseases in the Developing World Stephen J. Spann, M.D., M.B.A. Professor and Chairman Department of Family and Community Medicine.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Cardiovascular Risk: A global perspective
Nick Banatvala & Pascal Bovet
Kingdom of Bahrain Dr. Naeema Isa Al Sabaeei 2014
Scailing up responce to cardiovascular diseases in the Carribean
Management of Hypertension according to JNC 7
Dr John Cox Diabetes in Primary Care Conference Cork
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Nephrology Journal Club The SPRINT Trial Parker Gregg
Noncommunicable Diseases Surveillance in Egypt
Early detection and Management of CVD/NCD
Cardiovascular Disease Expert Consultation (PAHO)
Redefining Quality Care in T2DM Patients with CV Disease
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
ACCORD Design and Baseline Characteristics
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Implementing a National NCD Program Population Based and High Risk Approaches to Prevention and Control of NCDs/CVD Dr Shanthi Mendis MBBS MD FRCP.
Chronic Disease Prevention & Management World Health Organization
Epidemiology, Burden and Primary Prevention of Cardiovascular Disease Dr Shanthi Mendis MBBS MD FRCP FACC Coordinator Chronic Disease Prevention.
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
Prevention and Control of Noncommunicable Diseases
How does teamwork improve value. Dr Nils E
prevention and control of non communicable diseases in Iraq
What’s New in the 2013 ESC/ESH Hypertension Guideline
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Diabetes Health Status Report
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Prevention Cardiovascular disease
Teaching Tool: Blood Pressure Classification
Progress and Promise in RAAS Blockade
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
The Hypertension in the Very Elderly Trial (HYVET)
Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
ASCORE : An up-to-date cardiovascular risk score for hypertensive patients reflecting. contemporary clinical practices developed. using the ASCOT trial.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals & Guidelines A summary of international guidelines for CHD
Pharmacological Treatment of Hypertension Update 2012
Dr Timothy Armstrong Coordinator
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Reducing the NCD morbidity and mortality Using blood pressure and diabetes as entry points Shanthi Mendis MBBS MD FRCP FACC Senior Adviser Chronic Disease and Health Promotion World Health Organization Geneva, Switzerland

Is there justification to change the single risk factor approach? Yes How can this be operationalized ? What has been the experience of countries that have adopted the approach in EUR; WPR; AFRO, SEAR, EMR

Guideline with Risk Prediction charts Use BP or BG as entry points Full guideline Pocket version

All who need treatment should be treated Resources limited in most settings Match the nature and intensity of interventions with absolute risk of a heart attack or stroke Low risk does not = no risk Low risk group SHOULD NOT be ignored

Outcomes of Diabetes patients beyond cardiovascular risk CV Risk control (BP, BS, lipids) Nephropathy, Neuropathy, retinopathy, foot care Risk of people with Diabetes

What is it for ? Prevent cardiovascular disease (heart attacks, strokes, heart failure) By Assessment and reduction of CVR associated with raised blood pressure Assessment and reduction of CVR of diabetics (Majority of diabetic deaths are due to CVD) CVR=cardiovascular risk ... dhhfhfhdafaskhfhahfhd

Methodology Costly, labour intensive, several years Explicit evidence based methodology No funding from industry Experts declare conflicts of interest Extensive review

Pocket guideline Part 1= Reduce cardiovascular risk to prevent coronary/cerebral vascular disease Part II= Reduce cardiovascular risk in those with established coronary/cerebral vascular disease

What is the added value?

Added value Make hypertension programs cost effective, affordable, equitable Convey risk of an asymptomatic disease to people/community Integrates single risk factor approaches (hypertension /diabetes/hyperlipidemia) Match action & resources (countries can determine cut off for treatment )

Single risk factor approach Single RF approach works when RF are markedly high Commits patients with a small CVR to drug Rx while neglecting those with overall high risk. Does not take into account the continuous relationship between BP BC BS and CVR

How was it developed ?

WHO sub-regions

WHO/ISH risk prediction charts Charts for 14 WHO epidemiological subregions Each subregion has a group of countries Only one chart is applicable to any country Not for countries with existing risk charts CD in the full GL contain all charts Each pocket GL contain charts for one WHO region (AFR, AMR, EUR, SEAR, EMR, WPR) 14 charts with cholesterol and 14 without English version for AMR B countries (will explore ) The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

WHO/ISH risk prediction charts Predict 10 yr risk fatal/non fatal vascular events Charts use easy- to- measure variables Chart with / without diabetes Age, M/F, SBP, smoking, cholesterol Age, M/F, SBP, smoking The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

WHO/ISH risk prediction charts Modelling available data Cohort data not available for LMIC Accurate enough for risk stratification / clinical use Prediction accuracy will be refined when more data are available in countries Adding more variable would increase accuracy but reduce utility/cost effectiveness for LMIC The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

This is a real breakthrough ……..primary health care workers now have a new simple tool to assess and manage people at risk of heart attacks and strokes . This brings cardiovascular care to the places and people who need it most.` Dr Margaret Chan Director General WHO

Intensity of intervention should be proportional to the CVD risk

Cardiovascular risk levels (10 year combined AMI and stroke risk ) < 10% 10-20% 20-30% 30-40% >40% Overall, HIV/AIDS is the leading cause of death in adults aged 15–59. Ischaemic heart disease is the leading cause of death at older ages Note that 30% of deaths in developing countries occur in young adults – this vast premature adult mortality is a major public health concern

Match action with available resources National and local governments can decide on the 10 year risk cut off for intensive treatment (e.g. statins) High resource setting >10% Medium resource setting >20% Low resource setting >30% Very low resource setting >40%

Male 60 years Male 48 yrs Smoker Non smoker Non diabetic Non diabetic BP 150/95 TC 5 Low risk …….5% Smaller absolute reduction Male 60 years Smoker Non diabetic BP 155/95 TC 6 Medium risk …….15% Thiazide Higher absolute reduction The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

PHC Service delivery Next level Very low risk Manage in PHC (NPHW) Back referral Referral >40% 10-<20% 20-<30% 30-<40% Low Medium High Very high PHC (NPHW) Very low risk Manage in PHC

Issues Focus on elderly Accuracy (accurate enough as it is for treatment decisions) Risk ? (all people with very high levels of single RF get Rx) Validation will refine . If resources allow to be done for specific population (cohort study) Risk of those < 40 yrs

All risk groups need non-drug treatment Low risk non-drug treatment Medium risk add drugs as well High risk need intensive drug treatment (aspirin, antihypertensives, statin)

Prevention of CVD according to individual total risk

Cholesterol> 8 mmol/l Diabetes with nephropathy Manage as high risk BP 160-170/100-110 Cholesterol> 8 mmol/l Diabetes with nephropathy Established CHD, CeVD, PVD Target organ damage Renal failure The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

Charts under- estimate risk Already on antihypertensives Family history Obesity Raised TG >2 mmol/l Low HDL <1 mmol/l Microalbuminuria Raised homocysteine The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation

Simplified -Standardized care for heart attacks and strokes prevention Smoking cessation/PA/Diet Aspirin/ACEI/BB/Statins Referral Very High/High risk Step down Smoking cessation/PA/Diet Aspirin, HCT/ACEI/Statins Medium risk Smoking cessation/PA/Diet Low dose thiazide / Aspirin (may be) Low risk An important advance in assuring quality of care for patients was made by increasing the use of inhaled corticosteroids recommended by international guidelines. In most of the international guidelines several other drugs are recommended as cromones, long acting beta 2 agonist. As the IUATLD focus its activities in low income countries, the long term treatment recommended by the IUATLD Asthma Guide is based only on the 2 cost-effective inhaled drugs: salbutamol and beclomethasone. Smoking cessation/PA/Diet Very low risk GL : Diagnose/grade risk with simple indicators & Rx

Practice points The most cost effective drug Rx are aspirin and initial low dose thiazides. Intensive antihypertenisve Rx and statins are less cost effective. If limited resources, first offer aspirin and low dose thiazides to all. In diabetics, if resources are limited focus mainly on lowering BP and Rx of severe hypoglycemia .

Integrating diabetes and hypertension in PHC Develop and integrated guideline for PHC Use hypertension and diabetes as entry points

Integrating diabetes and hypertension in PHC What can a PHC worker do to prevent diabetic nephropathy? What can a PHC worker do to prevent limb amputation in Diabetic (foot care)? What can a PHC worker do to prevent diabetic retinopathy? What are the referral criteria for a diabetic? Diet /physical activity what special advise should be given for Diabetic patients? What insulin regimens can be maintained in PHC? What are the basic equipment and lab measurements needed in PHC for managing DM?

THANK YOU The contents of WHR 2003 focus on a selected number of current global health priorities The statistical annex summarises many aspects of the global health situation